

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 07405699869, email: info@vivanzabiosciences.com, web: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

27th May, 2022

To,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai — 400001.

Sub: Outcome of the Board Meeting

Scrip Code- 530057

Dear Sir/Madam,

In continuation of our letter dated 18th May, 2022, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, 27th May, 2022 at registered office of the Company has inter alia considered and approved the following:

- 1) Audited Standalone and Consolidated financial results of the company for the quarter and year ended on 31st March, 2022 and also took note of auditor's report thereon.
- 2) The issue of aggregate of 47,36,000 (Forty Seven Lakhs Thirty Six Thousand) convertible warrant on preferential basis to promoter, promoter group and to non promoters in accordance of chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("the ICDR Regulations") Preferential Allotment and subject to the approval of Regulatory/Statutory authority and members approval at ensuing Annual General Meeting.
- 3) Alteration of the Capital Clause of the Memorandum of Association ("MOA") of the Company.

Further, the brief details of alteration in MOA as required under Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 are annexed herewith marked as **Annexure-A**.

- 4) Appointment of Mr. Avinash G. Bhojwani as a Company Secretary and Compliance Officer of the Company and Terminate the service of Previous Company Secretary and Compliance Officer i.e.: Mrs. Aesha Mashru.
- 5) Investment in shares of Rs.6,64,330/- (Rupees Six Lakhs Sixty Four Thousand Three Hundred Thirty Only) which comprises of 30% of total capital of the Company in Vitaanova Healthcare Uganda Limited, a Uganda based Pharmaceutical Company.

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 07405699869, email: info@vivanzabiosciences.com, web: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057


- 6) Agenda for Appointment of Statutory Auditors has been dispensed with no conclusion as the same is not been approved in the Board.
- 7) Convening of Annual General Meeting of the Company on Wednesday, 13th July, 2022 through video conferencing and other audio visual means.

The meeting of Board of Directors of the Company commenced at 05:00 p.m. and concluded at 05:30 p.m.

You are requested to kindly take the same on record and acknowledge.

Thanking You,

For, Vivanza Biosciences Limited


Jainil Raseshkumar Bhatt
AJDPB2629L



VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 07405699869, email: info@vivanzabiosciences.com, web: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

Annexure-A

Summary of amendments in the MOA of the Company

Sr. No.	Changes
1.	<p>Existing Clause V of the Memorandum of Association of the Company has been substituted thereof by the following new Clause V as under:</p> <p>"V. The Authorised Capital of the Company is Rs. 9,00,00,000/- (Rupees Nine Crores Only) divided into 90,00,000 (Ninety Lacs) Equity Shares of Rs. 10/- (Rupees Ten Only) each subject to the increased or reduced in accordance with the Articles of Association of the Company and the legislative provisions for the time being in force with power to the Company to divide the shares in the capital for the time being whether original or increased or decreased or into several classes and to attach thereto respectively such ordinary, deferred, preferential or special rights and privileges and conditions in such manner as may be in accordance with the Company's regulations and the legislative provisions for time being in force in this behalf.</p>



UDIN: 22163940AJSYWU8680

To,
The Board of Directors
M/s Vivanza Biosciences Limited

Opinion

We have audited the accompanying standalone annual financial results of M/s Vivanza Biosciences Limited (hereinafter referred to as 'the Company') for the quarter and year ended March 31, 2022 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(ii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of Net Profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Standalone Financial Results

This Statement have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss and other comprehensive income in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other





irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the Override of internal control

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions





GMCA & Co.

Chartered Accountants

are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters


The Statement include the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

We have not attended the physical inventory verification at locations as it was impracticable under current lock down restrictions imposed by the government. Our Opinion is not modified in respect of the above matters.

Place: Ahmedabad
Date: 27/05/2022



For, G M C A & Co.
Chartered Accountants
FRN: 109850W


CA. Mitt S. Patel
Partner
Membership No. 163940

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

Tel No.: 079-26870952/54 Email : info@vivanzabiosciences.com Website : www.vivanzabiosciences.com

CIN : L24110GJ1982PLC005057

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2022

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended	
	31/03/2022	31/12/2021	31/03/2021	31/03/2022	31/03/2021
	Audited	Unaudited	Audited	Audited	Audited
1 Income from Operations					
(a) Revenue from operations	559.68	152.04	279.59	914.75	922.34
(b) Other Income	0.75	2.19	7.87	82.81	49.98
Total Income	560.43	154.23	287.46	997.56	972.32
2 Expenses					
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	396.71	447.17	258.67	1030.87	810.62
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	136.96	-317.83	12.33	-182.73	45.66
(d) Employee benefits expense	7.43	2.09	4.55	11.98	29.08
(e) Finance Cost	9.58	9.93	10.65	40.56	46.76
(f) Depreciation and amortisation expense	0.38	0.00	0.35	0.74	0.98
(g) Other expenses	26.83	12.61	11.26	49.72	24.42
Total Expenses	577.90	153.97	297.81	951.16	957.53
3 Profit/(loss) before exceptional items and tax (1-2)	-17.47	0.26	-10.35	46.41	14.79
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) before tax (3-4)	-17.47	0.26	-10.35	46.41	14.79
6 Tax Expense					
(a) Current tax	0.11	0.00	4.85	0.11	4.85
(b) Deferred tax	-0.07	0.00	-0.04	-0.07	-0.04
Total Tax Expenses	0.04	0.00	4.81	0.04	4.81
7 Profit / (Loss) for the period from continuing operations (5-6)	-17.51	0.26	-15.16	46.37	9.98
8 Profit (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
10 Profit (Loss) from discontinuing operations (after	0.00	0.00	0.00	0.00	0.00
11 Other Comprehensive Income					
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
Other Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income for the period	-17.51	0.26	-15.16	46.37	9.98
13 Paid-up equity share capital (Face value of Rs. 10/- each)	400	400	400	400	400
14 Other Equity	-	-	-	-17.12	-63.49
15 Earnings Per Share (before extraordinary items) (not annualised):					
(a) Basic	-0.44	0.01	-0.38	1.16	0.25
(b) Diluted	-0.44	0.01	-0.38	1.16	0.25
Earnings Per Share (after extraordinary items) (not annualised):					
(a) Basic	-0.44	0.01	-0.38	1.16	0.25
(b) Diluted	-0.44	0.01	-0.38	1.16	0.25


Notes:

1. The above standalone audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on May 27, 2022. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended March 31, 2022.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e. pharmaceuticals related activities

For, VIVANZA BIOSCIENCES LIMITED



JAINIL BHATT
CFO

PAN NO: AJDPB2629L

Date : 27/05/2022
Place : Ahmedabad

VIVANZA BIOSCIENCES LIMITED			
STATEMENT OF STANDALONE ASSETS AND LIABILITIES			
(Rs.in Lacs)			
Particulars	As at 31/03/2022	As at 31/03/2021	
A	ASSETS		
	1 Non-current Assets		
(a)	Property , Plant and Equipment	0.38	1.13
(b)	Other Intangible assets	-	-
(c)	Capital work in progress	-	-
(d)	Intangible assets under development	-	-
(e)	Financial Assets :	-	-
(i)	Investments	191.45	191.45
(ii)	Deferred tax assets (Net)	0.11	0.04
(iii)	Loans	-	-
(f)	Other non-current assets	59.33	59.33
	Sub-total - Non-current Assets	251.28	251.95
	2 Current Assets		
(a)	Inventories	222.54	39.81
(b)	Financial Assets :	-	-
(i)	Investments	-	-
(ii)	Trade Receivables	735.10	610.80
(iii)	Cash and Cash Equivalents	(271.73)	(311.27)
(iv)	Loans	190.29	187.16
(c)	Other current assets	19.81	14.74
	Sub-total - Current Assets	896.01	541.24
	TOTAL - ASSETS	1,147.29	793.18
B	EQUITY AND LIABILITIES		
	Shareholders' Funds		
(a)	Share Capital	400.00	400.00
(b)	Other Equity	(17.12)	(63.49)
	Sub-total - Shareholders' Funds	382.88	336.51
	1 Liabilities		
	Non-current Liabilities		
(a)	Financial Liabilities :	-	-
(i)	Borrowings	-	-
(b)	Deferred Tax Liabilities (Net)	-	-
(c)	Provisions	-	-
(d)	Other Non - Current Liabilities	-	-
	Sub-total - Non-current liabilities	-	-
	2 Current Liabilities		
(a)	Financial Liabilities :	-	-
(i)	Borrowings	168.40	17.53
(ii)	Trade Payables	548.48	386.48
(iii)	Other Financial Liabilities	-	-
(b)	Provisions	2.95	5.35
(c)	Other Current Liabilities	44.57	47.32
	Sub-total - Current Liabilities	764.40	456.67
	TOTAL - EQUITY AND LIABILITIES	1,147.29	793.18



VIVANZA BIOSCIENCES LIMITED

Cashflow Statement

(Rs.in Lacs)

Particulars	01-04-2021 to 31-03-2022	01-04-2020 to 31-03-2021
A Cash flow from Operating Activities		
Net Profit Before Tax	46.41	14.79
Adjustments for:		
Add Depreciation	0.74	0.98
Less Dividend Income	-	-
Add Interest Expense	40.56	46.76
Less Short Term Capital Gain (Mutual Fund)	-	-
Operating Profit / (Loss) before Working Capital Changes	87.71	62.54
Adjustments for:		
Increase/(Decrease) in Trade Payables	162.01	(427.82)
Increase/(Decrease) in Other Current Liabilities	(2.74)	(18.79)
Increase/(Decrease) in Provisions	(2.40)	2.09
(Increase)/Decrease in Trade Receivables	(124.30)	29.78
(Increase)/Decrease in short term loans & advances	-	-
Increase/(Decrease) in Borrowing	-	-
(Increase)/Decrease in inventories	(182.73)	45.62
(Increase)/Decrease in other current assets	(5.07)	3.68
Cashflow generated from Operating Activities	(67.53)	(302.91)
Income Tax Paid (Net of Refund)	0.19	4.89
Net Cashflow generated from Operating Activities A	(67.72)	(307.80)
B Cash flow from Investment Activities		
Purchase of Property , Plant and Equipment	-	(2.11)
Sale of Property , Plant and Equipment	-	-
Sale of Investments	-	-
Purchase of Investments	-	-
Share Application Money Received Back	-	-
Dividend Income	-	-
Net Cashflow generated from Investments Activities B	-	(2.11)
C Cash flow from Financing Activities		
Share Listing & Processing Fees	-	-
Interest Expenses	(40.56)	(46.76)
(Increase)/Decrease in other non-current assets	0.07	0.03
(Increase) /Decrease in Short term Loans & Advances (Assets)	(3.12)	326.60
Increase /(Decrease) in Borrowings (Liabilities)	150.87	-
Increase/(Decrease) in non current liabilities	-	-
Increase/(Decrease) in other financial liabilities	-	-
Net Cashflow generated from Financing Activities C	107.26	279.88
Net Change in Cash & Cash Equivalents (A+B+C)	39.54	(30.03)
Opening Cash & Cash Equivalents	(311.27)	(281.24)
Closing Cash & Cash Equivalents	(271.73)	(311.27)



**UDIN: 22163940AJSYBK5385**

To,
Board of Directors
M/s Vivanza Biosciences Limited

Report on the Audit of the Consolidated Annual Financial Results Opinion

We have audited the accompanying statement of quarterly and year to date consolidated financial results of M/s Vivanza Biosciences Limited ("Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter and year ended March 31, 2022, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiary, the aforesaid consolidated annual financial results:


- A. includes the annual financial results for the year ended 31st March 2022, of the following entities

Sr. No.	Particulars	Name of the Entity
1.	Subsidiary	Vivanza Life sciences Private Limited

- B. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard and
- C. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the consolidated net Profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the 'ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and that obtained by the other auditor in terms of





their report referred to in paragraph of the Other Matters section below, is sufficient and appropriate to provide a basis for our opinion.

Responsibility of Management for the Consolidated Annual Financial Results

The consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's management and Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these annual financial results that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Board of Directors of the companies included in the Group is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is also responsible for overseeing the financial reporting process of each company.

Auditor's Responsibility for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered





material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the consolidated annual financial results.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management
- Conclude on the appropriateness of Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any Significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all the





GMCA & Co.

Chartered Accountants

relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

We also performed procedures in accordance with the circular No CIRJCFD/CMD1/44/2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable


Other Matters

We did not audit the annual financial statements of one subsidiary included in the Statement for the year ended on that date, as considered in the Statement. These Annual Financial Statements have been audited by other auditor whose Audit report has been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures Include in respect of this subsidiary is based solely on the audit report of such other auditor, and the procedure performed by us as stated in paragraph above.

Place: Ahmedabad
Date: 27/05/2022



For, G M C A & CO.
Chartered Accountants
FRN No.:109850W


CA. Mitt S. Patel
Partner
Membership No. 163940

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

Tel No. : 079-26870952/54 Email : info@vivanzabiosciences.com Website : www.vivanzabiosciences.com

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2022

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended		
	31/03/2022	31/12/2021	31/03/2021	31/03/2022	31/03/2021	
	Audited	Unaudited	Audited	Audited	Audited	
1	Income from Operations					
	(a) Revenue from operations	584.53	152.04	290.57	1040.02	988.83
	(b) Other Income	29.47	2.19	10.33	82.89	50.56
	Total Income	614.00	154.22	300.90	1122.90	1039.39
2	Expenses					
	(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	420.41	448.05	262.78	1142.77	883.92
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	138.00	-318.71	14.62	-177.42	31.38
	(d) Employee benefits expense	9.63	6.54	5.31	29.62	33.91
	(e) Finance Cost	9.58	9.93	10.39	40.56	46.76
	(f) Depreciation and amortisation expense	0.38	0.00	0.35	0.74	0.98
	(g) Other expenses	27.26	13.17	15.47	53.28	30.09
	Total Expenses	605.26	158.98	308.92	1089.56	1027.04
3	Profit/(loss) before exceptional items and tax (1-2)	8.73	-4.76	-8.02	33.34	12.35
4	Exceptional Items	28.70	0.00	0.00	0.00	0.00
5	Profit/(Loss) before tax (3-4)	-19.97	-4.76	-8.02	33.34	12.35
6	Tax Expense					
	(a) Current tax	0.11	0.00	4.85	0.11	4.85
	(b) Deferred tax	-0.07	0.00	-0.04	-0.07	-0.04
	Total Tax Expenses	0.04	0.00	4.81	0.04	4.81
7	Profit / (Loss) for the period from continuing operations (5-6)	-20.00	-4.76	-12.83	33.30	7.54
8	Profit (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
9	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
10	Profit (Loss) from discontinuing operations (after	0.00	0.00	0.00	0.00	0.00
11	Other Comprehensive Income					
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	Other Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.00
12	Total Comprehensive Income for the period	-20.00	-4.76	-12.83	33.30	7.54
13	Paid-up equity share capital (Face value of Rs. 10/- each)	400	400	400	400	400
14	Other Equity	-	-	-	-	-84.06
15	Earnings Per Share (before extraordinary items) (not annualised):					
	(a) Basic	-0.50	-0.12	-0.32	0.83	0.19
	(b) Diluted	-0.50	-0.12	-0.32	0.83	0.19
16	Earnings Per Share (after extraordinary items) (not annualised):					
	(a) Basic	-0.50	-0.12	-0.32	0.83	0.19
	(b) Diluted	-0.50	-0.12	-0.32	0.83	0.19

Notes:

1. The above consolidated audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on May 27, 2022. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended March 31, 2022.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e. pharmaceuticals related activities



For, VIVANZA BIOSCIENCES LIMITED

JAINIL BHATT
CFO

PAN NO: AJDPB2629L

Date : 27/05/2022
Place : Ahmedabad

VIVANZA BIOSCIENCES LIMITED			
STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES			
(Rs.in Lacs)			
Particulars	As at 31/03/2022	As at 31/03/2021	
A	ASSETS		
	1 Non-current Assets		
(a)	Property , Plant and Equipment	68.21	68.95
(b)	Other Intangible assets (including Goodwill)	163.54	163.54
(c)	Capital work in progress	-	-
(d)	Intangible assets under development	-	-
(e)	Financial Assets :	-	-
(i)	Investments	0.25	0.25
(ii)	Deferred tax assets (Net)	0.11	0.04
(iii)	Loans	19.62	110.54
(f)	Other non-current assets	59.33	-
	Sub-total - Non-current Assets	311.06	343.32
	2 Current Assets		
(a)	Inventories	242.81	65.35
(b)	Financial Assets :	-	-
(i)	Investments	-	-
(ii)	Trade Receivables	784.04	625.06
(iii)	Cash and Cash Equivalents	(268.11)	(309.27)
(iv)	Loans	192.87	105.46
(c)	Other current assets	19.91	14.84
	Sub-total - Current Assets	971.51	501.44
	TOTAL - ASSETS	1,282.57	844.76
B	EQUITY AND LIABILITIES		
	Shareholders' Funds		
(a)	Share Capital	400.00	400.00
(b)	Other Equity	(50.75)	(84.06)
	Sub-total - Shareholders' Funds	349.25	315.94
	1 Liabilities		
	Non-current Liabilities		
(a)	Financial Liabilities :	-	-
(i)	Borrowings	259.65	-
(b)	Deferred Tax Liabilities (Net)	-	-
(c)	Provisions	-	-
(d)	Other Non - Current Liabilities	-	-
	Sub-total - Non-current liabilities	259.65	-
	2 Current Liabilities		
(a)	Financial Liabilities :	-	-
(i)	Borrowings	17.53	35.75
(ii)	Trade Payables	548.48	386.48
(iii)	Other Financial Liabilities	-	-
(b)	Provisions	3.99	6.97
(c)	Other Current Liabilities	103.67	99.62
	Sub-total - Current Liabilities	673.67	528.82
	TOTAL - EQUITY AND LIABILITIES	1,282.57	844.76



VIVANZA BIOSCIENCES LIMITED

Cashflow Statement

(Rs.in Lacs)

Particulars	01-04-2021 to 31-03-2022	01-04-2020 to 31-03-2021
A Cash flow from Operating Activities		
Net Profit Before Tax	33.34	12.35
Adjustments for:		
Add Depreciation	0.74	0.98
Less Dividend Income	-	-
Add Interest Expense	40.56	46.76
Less Short Term Capital Gain (Mutual Fund)	-	-
Operating Profit / (Loss) before Working Capital Changes	74.65	60.09
Adjustments for:		
Increase/(Decrease) in Trade Payables	162.01	(427.82)
Increase/(Decrease) in Other Current Liabilities	4.05	29.19
Increase/(Decrease) in Provisions	(2.98)	3.18
(Increase)/Decrease in Trade Receivables	(158.98)	28.84
(Increase)/Decrease in short term loans & advances	90.93	316.92
Increase/(Decrease) in Borrowing	259.65	(21.27)
(Increase)/Decrease in inventories	(177.46)	31.39
(Increase)/Decrease in other current assets	(5.07)	3.68
Cashflow generated from Operating Activities	246.79	24.20
Income Tax Paid (Net of Refund)	0.11	4.85
Net Cashflow generated from Operating Activities A	246.68	19.35
B Cash flow from Investment Activities		
Purchase of Property , Plant and Equipment	-	(2.11)
Sale of Property , Plant and Equipment	-	-
Sale of Investments	-	-
Purchase of Investments	-	-
Share Application Money Received Back	-	-
Dividend Income	-	-
Net Cashflow generated from Investments Activities B	-	(2.11)
C Cash flow from Financing Activities		
Share Listing & Processing Fees	-	-
Interest Expenses	(40.56)	(46.76)
(Increase)/Decrease in other non-current assets	(59.33)	-
(Increase) /Decrease in Short term Loans & Advances (Assets)	(87.41)	(20.27)
Increase /(Decrease) in Borrowings (Liabilities)	(18.22)	18.22
Increase/(Decrease) in non current liabilities	-	-
Increase/(Decrease) in other financial liabilities	-	-
Net Cashflow generated from Financing Activities C	(205.53)	(48.81)
Net Change in Cash & Cash Equivalents (A+B+C)	41.15	(31.57)
Opening Cash & Cash Equivalents	(309.26)	(277.69)
Closing Cash & Cash Equivalents	(268.11)	(309.26)

